OBJECTIVE: Uveitis in children most commonly is associated with juvenile idiopathic
arthritis. In addition to topical glucocorticoids, treatment may include systemic …

PURPOSE: To assess a response to infliximab therapy in childhood uveitis. DESIGN:
Retrospective case series. METHODS: We reviewed the course of 16 children with …

Background: Infliximab is a murine–human recombinant antitumour necrosis factor
monoclonal antibody recently introduced for the treatment of autoimmune diseases in which …

PURPOSE: To assess the response and adverse events associated with infliximab treatment
for refractory, noninfectious pediatric uveitis. DESIGN: Retrospective noncomparative case …

Objective. To describe efficacy and safety of infliximab in the treatment of childhood chronic
uveitis during a long-term follow-up. Methods. Fifteen patients (median age 12 yrs, range 5 …

Tumor necrosis factor-alpha (TNF-α) antagonists have been successfully used in refractory
cases of pediatric uveitis. 1-7 We report our experience with the monoclonal anti-TNF-α …

Objective. To describe the efficacy of anti-TNF-α agents in the treatment of childhood uveitis.
Methods. We performed a retrospective chart review of all children with uveitis treated with …

Objective. To evaluate the outcome of tumor necrosis factor-α inhibition (anti-TNF) for
pediatric uveitis. Methods. We retrospectively assessed children (age≤ 18 yrs) with …

Background. Infliximab (INF) has been shown to be beneficial in treating refractory uveitis,
however, no data exist on optimal dosing and the efficacy of higher dosing. Objectives. To …

Objective Infliximab, a monoclonal antibody against tumor necrosis factor α, is approved by
the US Food and Drug Administration for treatment of numerous autoimmune disorders. We …